Table 1. Overview of the efficacy of EGFR inhibitors in EGFR ex20ins-mutant NSCLC.
| Drug name | Year | Number of patients | ORR (%) | mPFS (months) | mOS (months) | Reference |
|---|---|---|---|---|---|---|
| Mobocertinib (TAK-788) | 2021 | 114 | 28 | 7.3 | 24 | (27) |
| Amivantamab (JNJ-372) | 2021 | 81 | 40 | 8.3 | 22.8 | (24) |
| CLN-081 (100 mg bid) | 2022 | 39 | 41 | 12 | NR | (29) |
| Sunvozertinib (DZD9008) | 2022 | 52 | 40.4 | NR | NR | (30) |
| Poziotinib | 2020 | 115 | 14.8 | 4.2 | NR | (31) |
| 2022 | 50 | 32 | 5.5 | NR | (32) | |
| Osimertinib | 2022 | 25 | 28 | 6.8 | NR | (33) |
| 2021 | 62 | 6.5 | 2.3 | NR | (35) | |
| Furmonertinib | 2022 | 15 | 53.5 | NR | NR | (34) |
| Afatinib | 2020 | 70 | 24.3 | NR | NR | (36) |
| 1st/2nd generation EGFR-TKIs | 2021 | 6 | 0 | 2 | 17 | (37) |
EGFR, epidermal growth factor receptor; ex20ins, exon 20 insertion; NSCLC, non-small cell lung cancer; ORR, overall response rate; mPFS, median progression-free survival; mOS, median overall survival; NR, not reported; TKI, tyrosine kinase inhibitor.